2020
DOI: 10.4103/ijabmr.ijabmr_360_19
|View full text |Cite
|
Sign up to set email alerts
|

Increasing prevalence of Escherichia coli and Klebsiella pneumoniae producing CTX-M-type extended-spectrum beta-lactamase, carbapenemase, and NDM-1 in patients from a rural community with community acquired infections: A 3-year study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 19 publications
(1 citation statement)
references
References 28 publications
0
1
0
Order By: Relevance
“…Resistance to carbapenems is attributable to one or more carbapenemase genes ( bla KPC , bla NDM , bla VIM , bla OXA−48 , and bla IMP−Like ), whose expression usually leads to carbapenem resistance [ 12 ]. However, since the first carbapenem-resistant strain of K. pneumoniae (KPC) was isolated and characterized in 1996 by Yigit et al, carbapenem-resistant strains have increased rapidly and have received considerable public interest due to the scarcity of antibiotic treatment choices [ 13 , 14 ]. The limited therapy choices resulting from the inefficacy of novel beta-lactam/beta-lactamase inhibitor combos, such as ceftazidime-avibactam and meropenem/vaborbactam against NDM-producing pathogens (New Delhi metallo beta-lactamase) constituted an additional barrier [ 15 ].…”
Section: Introductionmentioning
confidence: 99%
“…Resistance to carbapenems is attributable to one or more carbapenemase genes ( bla KPC , bla NDM , bla VIM , bla OXA−48 , and bla IMP−Like ), whose expression usually leads to carbapenem resistance [ 12 ]. However, since the first carbapenem-resistant strain of K. pneumoniae (KPC) was isolated and characterized in 1996 by Yigit et al, carbapenem-resistant strains have increased rapidly and have received considerable public interest due to the scarcity of antibiotic treatment choices [ 13 , 14 ]. The limited therapy choices resulting from the inefficacy of novel beta-lactam/beta-lactamase inhibitor combos, such as ceftazidime-avibactam and meropenem/vaborbactam against NDM-producing pathogens (New Delhi metallo beta-lactamase) constituted an additional barrier [ 15 ].…”
Section: Introductionmentioning
confidence: 99%